ApicHope Pharmaceutical Group Co., Ltd. (SHE:300723)
China · Delayed Price · Currency is CNY 33.82
+0.87 (2.64%)
At close: Feb 3, 2026
SHE:300723 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 993.66 | 1,419 | 2,489 | 2,275 | 2,195 | 1,675 |
Other Revenue | 30.76 | 30.76 | 14.04 | 4.95 | 3.82 | 0.21 |
| 1,024 | 1,450 | 2,503 | 2,280 | 2,199 | 1,675 | |
Revenue Growth (YoY) | -45.90% | -42.07% | 9.79% | 3.68% | 31.26% | 2.32% |
Cost of Revenue | 493.12 | 576.21 | 481.98 | 300.2 | 321.98 | 297.66 |
Gross Profit | 531.29 | 874.02 | 2,021 | 1,980 | 1,877 | 1,378 |
Selling, General & Admin | 827.14 | 829.71 | 1,414 | 1,464 | 1,447 | 1,034 |
Research & Development | 216.92 | 312.09 | 301.37 | 189.78 | 142.32 | 135.34 |
Other Operating Expenses | 33.87 | 24.35 | 72.86 | 30.39 | 30.44 | 21.5 |
Operating Expenses | 1,086 | 1,167 | 1,792 | 1,685 | 1,621 | 1,193 |
Operating Income | -554.39 | -293.44 | 229.35 | 294.58 | 256.25 | 184.38 |
Interest Expense | -53.25 | -35.11 | -37.65 | -28.96 | -38.51 | -11.75 |
Interest & Investment Income | 20.55 | 3.72 | 11.71 | 8.46 | 28.96 | 15.08 |
Currency Exchange Gain (Loss) | 1.31 | 1.31 | -5.51 | 0.1 | -0.47 | -0.09 |
Other Non Operating Income (Expenses) | 314.33 | -3.28 | -1.27 | -1.78 | -6.41 | -0.17 |
EBT Excluding Unusual Items | -271.45 | -326.79 | 196.63 | 272.4 | 239.82 | 187.44 |
Impairment of Goodwill | -11.03 | -11.03 | - | - | - | - |
Gain (Loss) on Sale of Investments | -0.46 | -40.11 | -24.64 | -28.31 | 23.96 | - |
Gain (Loss) on Sale of Assets | 1.68 | 1.27 | 0.12 | 0.19 | -0.07 | 0.03 |
Asset Writedown | -15.8 | -15.85 | -1.02 | -0.45 | -1.34 | -0.06 |
Other Unusual Items | -239.27 | -253.2 | 73.09 | 82.59 | 100.4 | 85.88 |
Pretax Income | -536.33 | -645.71 | 244.19 | 326.41 | 362.77 | 273.3 |
Income Tax Expense | -95.88 | -79 | 92.39 | 64.32 | 69.36 | 49.66 |
Earnings From Continuing Operations | -440.45 | -566.71 | 151.8 | 262.1 | 293.41 | 223.64 |
Minority Interest in Earnings | 10.87 | 26.67 | 32.82 | 28.59 | 13.5 | 1.97 |
Net Income | -429.58 | -540.04 | 184.61 | 290.68 | 306.92 | 225.61 |
Net Income to Common | -429.58 | -540.04 | 184.61 | 290.68 | 306.92 | 225.61 |
Net Income Growth | - | - | -36.49% | -5.29% | 36.04% | 57.02% |
Shares Outstanding (Basic) | 452 | 452 | 452 | 429 | 422 | 434 |
Shares Outstanding (Diluted) | 452 | 452 | 452 | 433 | 424 | 434 |
Shares Change (YoY) | -0.01% | -0.00% | 4.43% | 1.94% | -2.20% | 0.64% |
EPS (Basic) | -0.95 | -1.20 | 0.41 | 0.68 | 0.73 | 0.52 |
EPS (Diluted) | -0.95 | -1.20 | 0.41 | 0.67 | 0.72 | 0.52 |
EPS Growth | - | - | -39.18% | -7.09% | 39.10% | 56.02% |
Free Cash Flow | -467.41 | -870.18 | 123.59 | -130.25 | -123.13 | -38.93 |
Free Cash Flow Per Share | -1.03 | -1.93 | 0.27 | -0.30 | -0.29 | -0.09 |
Dividend Per Share | - | - | 0.210 | 0.133 | 0.133 | 0.093 |
Dividend Growth | - | - | 57.54% | - | 43.95% | 24.97% |
Gross Margin | 51.86% | 60.27% | 80.75% | 86.83% | 85.36% | 82.23% |
Operating Margin | -54.12% | -20.23% | 9.16% | 12.92% | 11.65% | 11.00% |
Profit Margin | -41.94% | -37.24% | 7.37% | 12.75% | 13.96% | 13.47% |
Free Cash Flow Margin | -45.63% | -60.00% | 4.94% | -5.71% | -5.60% | -2.32% |
EBITDA | -361.53 | -115.53 | 387.34 | 366.46 | 305.79 | 225.05 |
EBITDA Margin | -35.29% | -7.97% | 15.47% | 16.07% | 13.91% | 13.43% |
D&A For EBITDA | 192.86 | 177.91 | 157.99 | 71.89 | 49.54 | 40.68 |
EBIT | -554.39 | -293.44 | 229.35 | 294.58 | 256.25 | 184.38 |
EBIT Margin | -54.12% | -20.23% | 9.16% | 12.92% | 11.65% | 11.00% |
Effective Tax Rate | - | - | 37.84% | 19.70% | 19.12% | 18.17% |
Revenue as Reported | 1,024 | 1,450 | 2,503 | 2,280 | 2,199 | 1,675 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.